Advanced Research in Secondary Immunodeficiency in Oncohematological Diseases

Dear Colleagues,

A diverse range of illnesses known as secondary immunodeficiencies arise when the immune system is weakened by external causes. Recurrent infection is a common symptom of secondary immunodeficiency in people with hematological malignancies. Both the innate immunological deficiencies brought on by the cancer and the side effects of cancer treatments, many of which involve B-cell-depleting effects, contribute to secondary immunodeficiency. The early assessment of immune function in at-risk patient populations and the possibility of secondary immunodeficiency development are essential for creating a timely plan to prevent recurrent infections, which can be fatal or have a major negative impact on patients' quality of life and the continuation of cancer treatment regimens. A functional evaluation of the immune response to immunization is advised for these patients in order to bolster the diagnosis of secondary immunodeficiency. There are still many unanswered questions regarding the pathophysiology of secondary immunodeficiency, including the impact of various cellular and molecular mediators on the development of secondary immunodeficiency, as well as the combination of oxidative stress and non-coding genomic material. Additionally, distinct novel treatments for lymphoproliferative neoplasms, including bcl-2 inhibitors, bispecific antibodies, conjugated antibodies, and CAR-T cells, have the capacity to cause secondary immunodeficiency. In the same vein, more research is required to determine the optimal preventive and therapeutic measures, as well as how transplant therapy affects the capacity to cause immunodeficiency.

Prof. Dr. Giuseppe Murdaca
Prof. Dr. Sebastiano Gangemi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• secondary immunodeficiencies and opportunistic infections
• secondary immunodeficiencies and B-lymphocytes
• secondary immunodeficiencies and hematological diseases
• secondary immunodeficiencies and cancers
• secondary immunodeficiencies and novel cancer treatments
• secondary immunodeficiencies and oxidative stress